BAMCO Inc
TRIL

BAMCO Inc’s Trillium Therapeutics Inc. TRIL Stock Holding History

BAMCO Inc’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,671
Closed -$378K – 412
2020
Q4 		$378K Buy
25,671
+19,200
+297% +$277K ﹤0.01% 354
2020
Q3 		$92K Hold
6,471
– – ﹤0.01% 344
2020
Q2 		$52K Buy
+6,471
New +$40K ﹤0.01% 334

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BAMCO Inc's TRIL Position: Q1 2021 in Review

BAMCO Inc sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2021, closing a stake of 25,671 shares — an estimated $378K sold.

BAMCO Inc first reported a position in TRIL in Q2 2020 and held it in 3 quarters. The position peaked at $378K in Q4 2020. 125 funds tracked by Wall St. Rank hold TRIL as of Q1 2021.

  • BAMCO Inc reported no remaining Trillium Therapeutics Inc. position as of Q1 2021 after selling out during the quarter.
  • BAMCO Inc sold 25,671 Trillium Therapeutics Inc. shares in Q1 2021, an estimated $378K.
  • BAMCO Inc first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 3 quarters.
  • BAMCO Inc's Trillium Therapeutics Inc. position peaked at $378K in Q4 2020.
  • 125 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2021.

Based on BAMCO Inc's 13F filing for Q1 2021, filed 19 May 2021.